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Summary
Background Previous prospective cohort studies have shown that angiogenic factors have a high diagnostic accuracy 
in women with suspected pre-eclampsia, but we remain uncertain of the effectiveness of these tests in a real-world 
setting. We therefore aimed to determine whether knowledge of the circulating concentration of placental growth 
factor (PlGF), an angiogenic factor, integrated with a clinical management algorithm, decreased the time for 
clinicians to make a diagnosis in women with suspected pre-eclampsia, and whether this approach reduced 
subsequent maternal or perinatal adverse outcomes.
Methods We did a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial in 11 maternity units 
in the UK, which were each responsible for 3000–9000 deliveries per year. Women aged 18 years and older who 
presented with suspected pre-eclampsia between 20 weeks and 0 days of gestation and 36 weeks and 6 days of 
gestation, with a live, singleton fetus were invited to participate by the clinical research team. Suspected pre-
eclampsia was defined as new-onset or worsening of existing hypertension, dipstick proteinuria, epigastric or right 
upper-quadrant pain, headache with visual disturbances, fetal growth restriction, or abnormal maternal blood tests 
that were suggestive of disease (such as thrombocytopenia or hepatic or renal dysfunction). Women were 
approached individually, they consented for study inclusion, and they were asked to give blood samples. We 
randomly allocated the maternity units, representing the clusters, to blocks. Blocks represented an intervention 
initiation time, which occurred at equally spaced 6-week intervals throughout the trial. At the start of the trial, all 
units had usual care (in which PlGF measurements were also taken but were concealed from clinicians and 
women). At the initiation time of each successive block, a site began to use the intervention (in which the circulating 
PlGF measurement was revealed and a clinical management algorithm was used). Enrolment of women continued 
for the duration of the blocks either to concealed PlGF testing, or after implementation, to revealed PlGF testing. 
The primary outcome was the time from presentation with suspected pre-eclampsia to documented pre-eclampsia 
in women enrolled in the trial who received a diagnosis of pre-eclampsia by their treating clinicians. This trial is 
registered with ISRCTN, number 16842031.
Findings Between June 13, 2016, and Oct 27, 2017, we enrolled and assessed 1035 women with suspected pre-eclampsia. 
12 (1%) women were found to be ineligible. Of the 1023 eligible women, 576 (56%) women were assigned to the 
intervention (revealed testing) group, and 447 (44%) women were assigned to receive usual care with additional 
concealed testing (concealed testing group). Three (1%) women in the revealed testing group were lost to follow-up, 
so 573 (99%) women in this group were included in the analyses. One (<1%) woman in the concealed testing group 
withdrew consent to follow-up data collection, so 446 (>99%) women in this group were included in the analyses. 
The median time to pre-eclampsia diagnosis was 4·1 days with concealed testing versus 1·9 days with revealed testing 
(time ratio 0·36, 95% CI 0·15–0·87; p=0·027). Maternal severe adverse outcomes were reported in 24 (5%) of 
447 women in the concealed testing group versus 22 (4%) of 573 women in the revealed testing group (adjusted 
odds ratio 0·32, 95% CI 0·11–0·96; p=0·043), but there was no evidence of a difference in perinatal adverse outcomes 
(15% vs 14%, 1·45, 0·73–2·90) or gestation at delivery (36·6 weeks vs 36·8 weeks; mean difference –0·52, 95% CI 
–0·63 to 0·73).
Interpretation We found that the availability of PlGF test results substantially reduced the time to clinical confirmation 
of pre-eclampsia. Where PlGF was implemented, we found a lower incidence of maternal adverse outcomes, consistent 
with adoption of targeted, enhanced surveillance, as recommended in the clinical management algorithm for 
clinicians. Adoption of PlGF testing in women with suspected pre-eclampsia is supported by the results of this study.
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Introduction
Hypertension affects 10% of pregnant women, and 
pre-eclampsia complicates around 3% of singleton 
pregnancies.1,2 Women with pre-eclampsia are often 
asymptomatic, even those with severe disease. Diagnosis 
is based on clinical features such as hypertension and 
raised urinary protein excretion, both of which are subject 
to observer error,3 heterogeneity in test accuracy,4,5 and an 
insufficient ability of clinicians to predict important 
adverse pregnancy outcomes.6 The presentation of 
pre-eclampsia is often clinically ambiguous, and risk 
stratification of women with suspected pre-eclampsia is 
complex. This ambiguity leads to repeated hospital 
attendances for antenatal monitoring, increased use of 
health resources,7 and considerable anxiety for women, 
while missing at-risk cases.8
Angiogenic factors are associated with the patho-
physiology of pre-eclampsia.9,10 In a study11 of the accuracy 
of tests in diagnosing pre-eclampsia, low circulating 
maternal placental growth factor (PlGF) concentrations 
had a high sensitivity (96%; 95% CI 89–99) and negative 
predictive value (98%; 93–99·5) in diagnosing pre-
eclampsia that required delivery within 14 days in women 
who presented with suspected pre-eclampsia. In this 
study, the area under the receiver operating characteristic 
curve for low PlGF concentrations in determining pre-
eclampsia was 0·87 (SE 0·03), which is greater than all 
commonly used tests in the maternity assessment setting 
(such as for blood pressure, alanine transaminase, and 
urate).
Many diagnostic tests enter clinical care without being 
evaluated in a trial to assess whether the test makes a 
difference to diagnosing the condition it is intended for, 
whether use of the test affects downstream outcomes 
when implemented into practice, or whether diagnostic 
test performance is maintained in a real-world setting. 
There is a need to determine whether measurement of 
these novel angiogenic factors (such as PlGF) in pregnant 
women could translate into improved diagnosis and care 
when implemented into clinical practice. We therefore 
aimed to determine whether knowledge of circulating 
PlGF concentration, integrated with a clinical manage-
ment algorithm, decreased the time for clinicians to 
make a diagnosis in women with suspected pre-
eclampsia. We also aimed to determine whether this 
approach reduced subsequent maternal or perinatal 
adverse outcomes.
Methods
Study design and participants
We did a multicentre, pragmatic, stepped-wedge cluster-
randomised controlled trial in 11 UK maternity units, 
which were each responsible for 3000–9000 deliveries 
per year. Women aged 18 years and older who presented 
with suspected pre-eclampsia between 20 weeks and 
0 days and 36 weeks and 6 days of gestation, with a live, 
Research in context
Evidence before this study
We searched PubMed, ClinicalTrials.gov, and the ISRCTN registry 
for original articles published in English before Oct 1, 2018, 
with the search terms “pre-eclampsia AND angiogenic factor OR 
placental growth factor AND/OR trial”. We found no published 
trials that evaluated the implementation of angiogenic factors 
(such as placental growth factor [PlGF]) as a diagnostic adjunct 
in women presenting with suspected pre-eclampsia. However, 
we identified three trials from registry searches. We found a small 
(n=366), single-centre, retrospectively registered clinical trial, 
but the results of this trial have not yet been published. 
Two other multicentre trials are ongoing (still recruiting) in 
Ireland and Spain, both of which aim to evaluate whether 
incorporation of PlGF-based testing into current management 
algorithms improves maternal and perinatal outcomes in 
women with suspected pre-eclampsia. Previous cohort studies 
have demonstrated high sensitivity and a negative predictive 
value of PlGF-based testing in determining the need for delivery 
in women with suspected pre-eclampsia, but this testing has not 
been assessed within a trial.
Added value of this study
Our stepped-wedge cluster-randomised controlled trial provides 
evidence of the clinical effects of PlGF-based testing on the time 
to diagnosis and maternal and perinatal outcomes in women 
with suspected pre-eclampsia. In 11 hospitals across the UK, 
we implemented PlGF-based testing alongside a clinical 
management algorithm that was based on national guidance. 
We found a significant reduction in the time taken for a clinician 
to make a diagnosis of pre-eclampsia when using PlGF-based 
testing relative to routine clinical care. This approach was found 
to be associated with a reduction in severe maternal adverse 
outcomes, with no difference seen in gestational age at delivery 
or perinatal adverse outcomes. To our knowledge, our study is the 
first multicentre randomised controlled trial of PlGF-based testing 
as a diagnostic adjunct for women with suspected pre-eclampsia.
Implications of all the available evidence
Angiogenic factors have previously shown good performance in 
determining the need for delivery in women presenting with 
suspected pre-eclampsia. Our trial has demonstrated that, 
with implementation of PlGF-based testing, clinicians make a 
quicker diagnosis of pre-eclampsia and there is an associated 
reduction in serious maternal adverse events. The clinical use of 
PlGF measurement could present a change for antenatal care 
that improves speed of diagnosis and improves outcomes in 
pregnancy. Our findings provide novel evidence supporting the 
adoption of PlGF testing as a diagnostic adjunct for suspected 
pre-eclampsia. Evaluation of the intervention with women 
stratified by PlGF category could further elucidate the 
mechanisms by which PlGF testing and our management 
algorithm affect maternal outcomes.
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singleton fetus were invited to participate. Women were 
identified as having suspected pre-eclampsia at routine 
antenatal appointments or following an acute clinical 
presentation with symptoms, but women with a 
documented diagnosis of pre-eclampsia at presentation 
were ineligible. Suspected pre-eclampsia was defined 
as new-onset or worsening of existing hypertension, 
dipstick proteinuria, epigastric or right upper-quadrant 
pain, a headache with visual disturbances, fetal growth 
restriction, or abnormal maternal blood tests that were 
suggestive of disease (such as thrombocytopenia or 
hepatic or renal dysfunction). Since a very low PlGF 
result might have been concerning to some health-care 
professionals and women, with the unintended effect of 
increasing non-indicated preterm delivery, we made it 
clear in written information and training that a PlGF 
result was not an indication for delivery in itself. All 
participants provided individual written consent. The 
trial was approved by the London South East Research 
Ethics Committee (no. 15/LO/2058).
Randomisation and masking
Women were approached individually, they consented to 
inclusion in the study, and they were asked for blood 
samples. We randomly allocated the maternity units, 
representing the clusters, to blocks. Blocks represented 
an intervention initiation time, which occurred at equally 
spaced 6-week intervals throughout the trial. At the start 
of the trial, all units had usual care (in which PlGF 
measurements were also taken but were concealed from 
clinicians and women). At the initiation time of each 
successive block, a site began to use the intervention 
(in which the circulating PlGF measurement was 
revealed and a clinical management algorithm was used). 
Enrolment of women continued for the duration of 
the blocks either to concealed PlGF testing (before 
implementation) or, after implementation, to revealed 
PlGF testing. The centres were randomly allocated to the 
order in which the intervention was introduced by the 
trial statistician (PTS), who did the trial analyses. This 
ran dom allocation accounted for the number of deliveries 
per month, such that the rank correlation between 
delivery rate and the order of randomisation was zero. 
We used the rank correlation to balance the allocation 
order by number of women delivering per month, so the 
sites were evenly distributed between blocks in this 
regard, ensuring that the larger units or smaller units did 
not all receive the intervention at the beginning or the 
end of the trial. PlGF measurement was not routinely 
available in any of the sites before the trial and, for the 
duration of the trial, PlGF measurement was not used 
outside of the study in any of the sites, as confirmed on 
site visits and team teleconferences throughout the trial.
Procedures
Before implementation of the intervention, in the usual 
care time period, additional blood samples were taken 
from all women participating and were processed at each 
unit within 4 h of sampling on an electronically-masked 
Triage instrument (Quidel Cardiovascular Inc; San Diego, 
CA), according to the manufacturer’s instructions, which 
confirmed that the test had been successfully processed 
but without revealing a result. The usual care pathway 
followed local hospital practice, the National Institute 
for Health and Care Excellence (NICE) guidelines for 
management of hypertension in pregnancy,12 and national 
guidance for management of fetuses suspected to be 
small for gestational age.13
The trial consisted of 12 6-week blocks. One unit 
transitioned to the intervention at the start of each block, 
following an initial block in which all maternity units 
used usual care with concealed testing. We informed 
units 6 weeks before their transition to the intervention, 
to allow time for training in the incorporation of PlGF 
measurements into current NICE management of 
hypertension in pregnancy, the mainstay of manage-
ment. At transition, a meter to show revealed results and 
a training package, including a management algorithm, 
were provided; this package incorporated PlGF mea-
surement into the NICE guidance for the management 
of hyper tensive pregnancies (appendix). A short training 
session was given by the trial team to describe integration 
of PlGF testing into current management guidelines. At 
the time of the last block, all participating units were 
using this intervention.
Outcomes
All outcomes were assessed on an individual level by 
intention to treat. The primary outcome was the time in 
days from trial entry to a documented diagnosis of pre-
eclampsia, as defined by the International Society for 
the Study of Hypertension in Pregnancy (ISSHP) 2014 
statement,14 in each woman’s clinical notes. PlGF 
measure ments were not a component of the clinical 
diagnosis, since this test is not included within the 
ISSHP diagnostic criteria. Every diagnosis, including all 
diagnosed cases of pre-eclampsia, was also reviewed by a 
central adjudication panel who were masked to trial 
allocation. All diagnosed cases of pre-eclampsia were 
verified by a central adjudication team consisting of a 
clinical doctor and a research midwife, who were also 
masked to site allocation and PlGF result, at periodic 
data review meetings throughout the trial. The time to 
diagnosis was reviewed in the case notes, and all cases had 
to meet the ISSHP criteria for diagnosis of pre-eclampsia. 
Any discrepancies between the notes and the adjudication 
panel were sent for independent review by the chief 
investigator, who remained masked to group allocations 
until data were analysed.
The prespecified secondary maternal outcomes were a 
composite of severe maternal adverse events, as defined 
by the fullPIERS consensus.15 These adverse outcomes 
were reported as the number of women with one event or 
more of: maternal death, eclampsia, a Glasgow Coma 
See Online for appendix
Articles
4 www.thelancet.com   Published online April 1, 2019   http://dx.doi.org/10.1016/S0140-6736(18)33212-4
Scale score of less than 13, stroke, transient ischaemic 
attack, cortical blindness or retinal detachment, posterior 
reversible encephalopathy, a requirement for positive 
inotropic support, a requirement for parenteral infusion 
of a third-line antihypertensive, myocardial ischaemia or 
infarction, blood oxygen saturations of less than 90%, 
50% FiO2 (or higher) for more than 1 h, a requirement for 
intubation (other than for caesarean section), pulmonary 
oedema, a requirement for transfusion of blood products, 
a platelet count of less than 50 × 10⁹ platelets per L, hepatic 
dysfunction, haematoma or hepatic rupture, severe acute 
kidney injury (defined as concentrations of creatinine 
>150 µmol/L or >200 µmol/L in chronic kidney disease, a 
requirement for dialysis), or placental abruption. We also 
tested for the secondary maternal outcomes of systolic 
blood pressure of more than 160 mm Hg, progression to 
severe pre-eclampsia, placental abruption, mode and 
onset of delivery, and PlGF test performance in women 
presenting before 35 weeks of gestation and that in 
women presenting between 35 weeks and 0 days and 
36 weeks and 6 days of gestation for clinically-indicated 
delivery within 14 days of trial entry. Because of concerns 
over selection bias, we have reported and tested the 
proportion of women reaching the diagnostic criteria, 
irrespective of clinical confirmation of pre-eclampsia. We 
also assessed several additional descriptive secondary 
maternal outcomes post hoc, after peer review.
The prespecified secondary perinatal outcomes were 
gestation at delivery, preterm birth before 37 weeks of 
gestation, birthweight and birthweight centile,16 Apgar 
scores at 5 min after birth, admission to a neonatal unit, 
perinatal death (defined as deaths from 24 weeks of 
gestation, including those defined as stillbirths, until 
7 completed days after birth), and late neonatal deaths 
(deaths between 8 and 27 complete days after birth). 
Severe perinatal morbidity and mortality was an 
additional secondary composite perinatal outcome that 
was assessed post hoc, which comprised the number of 
babies with one event or more of: necrotising enterocolitis 
stage 2 and 3, retinopathy of prematurity, intraventricular 
haemorrhage, respiratory distress syn drome, seizures, 
bronchopulmonary dysplasia, still birth, early neonatal 
death, and late neonatal death before or at 28 days.
Maternal health care resource use outcomes comprised 
outpatient attendances and inpatient nights in hospital. 
Neonatal resource use outcomes were nights in the 
highest-level care (intensive and high-dependency care) 
and special care.17 These outcomes were prespecified.
Two prespecified sensitivity analyses on the primary 
outcome were done: the first analysis was for all women 
with a pre-eclampsia diagnosis (both a clinical diagnosis, 
and a diagnosis following adjudication by the trial team), 
and the second analysis was for women diagnosed within 
4 weeks of enrolment, censoring diagnoses at 4 weeks 
from trial entry.
Statistical analysis
We based our estimates on the PELICAN study,11 from 
which we assumed that 58% of women presenting with 
suspected pre-eclampsia will later be diagnosed with the 
disease. We specified a high intracluster correlation 
(0·3) to confirm that we would have adequate power 
under plausible circumstances. We required at least 
12 women with suspected pre-eclampsia per unit 
(in six maternity units) per time frame, giving a required 
sample size of 504 women (from which we would 
find an estimated 294 cases). This design and sample 
size gave us more than 95% power (by the method by 
Hemming and colleagues)18 to show a 50% reduction in 
mean time to diagnosis from 14 days (SD 14) to 7 days, 
assuming a minimum of six maternity units. We chose a 
50% reduction for time to diagnosis as a possible effect 
Figure 1: Trial profile
Revealed resting
Usual care with concealed 
resting
Implementation of the intervention
 Block 
1 
Block 
2  
Block 
3 
Block 
4 
Block 
5 
Block 
6 
Block 
7 
Block 
8 
Block 
9 
Block 
10 
Block 
11 
Block 
12 
Site 1 
Site 2 
Site 3 
Site 4
Site 5 
Site 6 
Site 7 
Site 8 
Site 9 
Site 10 
Site 11 
11 clusters assessed for eligibility
11 clusters analysed
1035  participants enrolled
1023 were tested for placental growth factor
576 allocated to revealed testing (intervention)
576 received revealed testing
12 excluded (did not meet inclusion criteria)
6 had confirmed pre-eclampsia
3 at more than 37 weeks’ gestation
1 with twin pregnancy
1 woman younger than 18 years
1 no indication for testing
11 clusters randomly assigned to blocks
3 lost to follow-up
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of the intervention that was plausible, notable, and likely 
to affect clinical practice.
At the trial planning stage, 11 maternity units confirmed 
participation and, post hoc, our intracluster correlation 
was 0·035, which was much lower than we allowed for 
in the power calculation (thereby increasing the study 
power). However, the actual proportion of women 
diagnosed with pre-eclampsia was found to be lower 
than anticipated. This reduced proportion of women 
diagnosed was offset by more sites participating than 
originally planned.
The primary outcome (time to diagnosis with pre-
eclampsia) was assessed by linear regression of logged 
time to diagnosis by use of robust standard errors19 
(in those who were clinically diagnosed with pre-
eclampsia) and was presented as adjusted ratios of 
geometric means. We adjusted for centre, time, gesta-
tional age at entry, and three covariates prespecified to 
potentially affect the primary outcome: previous pre-
eclampsia, chronic hypertension, and chronic kidney 
disease. A log trans formation was used because the data 
were log-normally distributed when data were inspected 
before unmasking. We did not include attending clinician 
in the model because pregnant women in the UK National 
Health Service health-care setting are routinely man-
aged by several health-care professionals (including 
obstetricians and midwives), with clinical decisions often 
being made by a consensus among multiple clinicians. 
The relevant dates and times were entered on the database 
with a 24-h clock, but time to diagnosis was presented in 
days (rather than hours) because this approach is the 
most pragmatic (when time progresses beyond 24 h) 
and clinically meaningful. One prespecified sensitivity 
analysis was done with linear regression of all women 
with a pre-eclampsia diagnosis by either the clinicians or 
the trial team, with undiagnosed pre-eclampsia treated as 
diagnosed at delivery. For the other sensitivity analysis, 
we used a parametric survival analysis on data from 
all women with a pre-eclampsia diagnosis, censoring 
diagnoses at 4 weeks from trial entry. We prespecified the 
Revealed PlGF 
(intervention; 
n=576)
Concealed PlGF 
(n=447)
Age, years 31·9 (5·9) 31·5 (6·0)
Ethnicity
White 378 (66%) 292 (65%)
Black 76 (13%) 63 (14%)
Indian, Pakistani, Bangladeshi, 
or Sri Lankan
67 (12%) 52 (12%)
Mixed 13 (2%) 11 (2%)
Other (including Chinese) 39 (7%) 26 (6%)
Body-mass index, kg/m² 27·9 (23·9–33·1) 28·4 (24·2–34·1)
Previous pregnancies with durations of 24 weeks or more
0 317 (55%) 211 (47%)
1 133 (23%) 120 (27%)
2 59 (10%) 65 (15%)
≥3 67 (12%) 51 (11%)
Number of previous pregnancies with durations of less than 24 weeks*
0 449 (78%) 318 (71%)
1 65 (11%) 81 (18%)
≥2 45 (8%) 47 (11%)
Previous pre-eclampsia 
(of multiparous women)
99 (38%) of 259 92 (39%) of 236
Pre-existing chronic 
hypertension
87 (15%) 70 (16%)
Pre-existing renal disease 24 (4%) 17 (4%)
Diabetes before pregnancy 31 (5%) 26 (6%)
Blood pressure at initial antenatal visit, mm Hg
Systolic 120 (15) 120 (16)
Diastolic 74 (11) 72 (12)
Being prescribed prophylactic 
aspirin
235 (41%) 178 (40%)
Has gestational diabetes 71 (12%) 53 (12%)
Presenting signs and symptoms†
New-onset hypertension 299 (52%) 209 (47%)
Worsening of existing 
hypertension
100 (17%) 79 (18%)
New-onset proteinuria 341 (59%) 263 (59%)
Epigastric or right 
upper-quadrant pain
47 (8%) 47 (11%)
Neurological symptoms 187 (32%) 150 (34%)
Suspected fetal growth 
restriction
103 (18%) 62 (14%)
Abnormal blood test results 19 (3%) 8 (2%)
Reduced fetal movement 6 (1%) 5 (1%)
Gestation at enrolment, weeks 32·3 (3·8) 32·7 (3·9)
(Table 1 continues in next column)
Revealed PlGF 
(intervention; 
n=576)
Concealed PlGF 
(n=447)
(Continued from previous column)
Highest blood pressure in the 48 h before study entry, mm Hg
Systolic 144 (20) 143 (20)
Diastolic 91 (14) 91 (13)
Highest dipstick proteinuria in the 48 h before study entry
None 207 (37%) 170 (38%)
Trace 60 (11%) 57 (13%)
1+ 153 (27%) 108 (24%)
≥2+ 147 (26%) 111 (25%)
Mean PlGF, pg/mL 186 (277) 202 (355)
Median PlGF, pg/mL 55 (13–235) 39 (12–236)
PlGF, pg/mL
<12 130 (23%) 106 (24%)
12–100 213 (37%) 173 (39%)
>100 230 (40%) 167 (37%)
Data are mean (SD), n (%), or median (IQR). PlGF=placental growth factor. 
*Including previous miscarriages, ectopic pregnancies, and terminations of 
pregnancy at less than 24 weeks of gestation. †Women could have more than 
one sign or symptom. 
Table 1: Baseline demographics and clinical characteristics
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4-weeks timepoint to reflect previous studies20 that have 
reported time to delivery within 4 weeks.
Secondary outcomes were analysed with linear 
regression, adapting with log transformation where 
Revealed PlGF 
(intervention; 
n=573)
Concealed PlGF 
(n=446)
Primary outcome
Number diagnosed with pre-eclampsia 205 (36%) 155 (35%)
Time to diagnosis of pre-eclampsia in 
those diagnosed, days
1·9 
(0·5–9·2)
4·1 
(0·8–14·7)
Secondary maternal outcomes
Number of women with adverse 
outcomes, defined by the fullPIERS 
consensus*
22 (4%) 24 (5%)
Maternal deaths 0 0
Eclampsia 0 2 (<1%)
Stroke 0 2 (<1%)
Parenteral infusion of third-line 
antihypertensive required
1 (<1%) 3 (1%)
Myocardial infarction 0 1 (<1%)
Blood oxygen saturation <90% 1 (<1%) 1 (<1%)
Intubation required (other than for 
caesarean section)
0 1 (<1%)
Pulmonary oedema 2 (<1%) 0
Transfusion of blood products 
required
9 (2%) 14 (3%)
Platelet count <50 × 10⁹ platelets 
per L
4 (1%) 4 (1%)
Hepatic dysfunction 1 (<1%) 0
Severe acute kidney injury 7 (1%) 6 (1%)
Dialysis required 0 1 (<1%)
Placental abruption 4 (1%) 5 (1%)
Primary diagnosis
Pre-eclampsia 175 (31%) 126 (28%)
Superimposed pre-eclampsia 30 (5%) 29 (7%)
Gestational hypertension 100 (17%) 77 (17%)
Gestational proteinuria 29 (5%) 20 (4%)
Small-for-gestational-age infant 
only
32 (6%) 28 (6%)
Chronic hypertension only 37 (6%) 28 (6%)
Chronic hypertension with a 
small-for-gestational-age infant
11 (2%) 9 (2%)
Renal disease 7 (1%) 4 (1%)
Transient hypertension 8 (1%) 20 (4%)
None of the above 94 (16%) 63 (14%)
Subsequent diagnosis of 
pre-eclampsia by adjudication team
50 (9%) 42 (9%)
Number with pre-eclampsia, 
diagnosed by adjudication
255 (44%) 197 (44%)
Severe pre-eclampsia 155 (27%) 106 (24%)
Time to diagnosis of pre-eclampsia 
(of those diagnosed within 4 weeks 
of trial entry), days
1·3 
(0·3–6·0)
2·7 
(0·7–8·9)
Fetal growth abnormalities on ultrasound*
Received a scan 438 (77%) 307 (69%)
Any growth abnormality identified 142 (25%) 67 (22%)
Estimated fetal weight of less than 
the tenth percentile
117 (27%) 62 (20%)
Absent or reversed end-diastolic 
flow
43 (10%) 16 (5%)
(Table 2 continues in next column)
Revealed PlGF 
(intervention; 
n=573)
Concealed PlGF 
(n=446)
(Continued from previous column)
Use of antihypertensives 347 (61%) 270 (61%)
Systolic blood pressure of at least 
160 mm Hg
239 (42%) 188 (42%)
Labour onset
Spontaneous 79 (14%) 78 (17%)
Induced 263 (46%) 210 (47%)
Pre-labour caesarean section 230 (40%) 158 (35%)
Preterm deliveries <37 weeks 234 (41%) 167 (37%)
Indication for induction or caesarean section before labour†
Maternal hypertension not 
controlled by maximal therapy
25 (5%) 28 (8%)
Maternal haematological 
abnormality
10 (2%) 3 (1%)
Maternal biochemical abnormality 15 (3%) 16 (4%)
Fetal compromise on ultrasound 34 (7%) 19 (5%)
Fetal compromise on 
cardiotocography
31 (6%) 40 (11%)
Severe maternal symptoms of 
pre-eclampsia
48 (10%) 27 (7%)
Diagnosis of pre-eclampsia and 
reaching 37 weeks of gestation
65 (13%) 57 (16%)
Gestational hypertension and 
reaching 37 weeks of gestation
56 (11%) 37 (10%)
Chronic hypertension and reaching 
37 weeks of gestation
27 (6%) 17 (5%)
Enrolled in PHOENIX trial 13 (3%) 9 (2%)
Other obstetric complications 170 (34%) 115 (31%)
Mode of delivery
Spontaneous vaginal cephalic 210 (37%) 182 (41%)
Assisted vaginal (forceps or vacuum) 42 (7%) 38 (9%)
Vaginal breech 1 (<1%) 2 (<1%)
Pre-labour caesarean section 170 (30%) 130 (29%)
In-labour caesarean section 150 (26%) 94 (21%)
Major post-partum haemorrhage 49 (9%) 48 (11%)
Maternal health resource use
Mean outpatient visits (SE) 6·14 (0·53) 9·44 (0·81)
Mean inpatient nights (SE) 7·43 (0·36) 7·26 (0·38)
Data are n (%), median (IQR), or mean (SD), unless otherwise indicated. For all 
fullPIERS outcome data not provided, no women had any of these events. Hepatic 
dysfunction was defined as an international normalisation ratio of more than 
1·2 in the absence of disseminated intravascular coagulation (defined as abnormal 
bleeding and consumptive coagulopathy—ie, low platelets, abnormal peripheral 
blood film, or any of increased international normalisation ratio, increased 
activated partial thromboplastin time, low fibrinogen, or increased fibrin 
degradation products that are outside normal non-pregnancy ranges) or 
treatment with warfarin. Time ratio for the time to diagnosis of pre-eclampsia 
(primary outcome) 0·36 (95% CI 0·15–0·87). PlGF=placental growth factor.  
*Women could have several adverse events. †Of 494 women in the revealed 
group and 368 women in the concealed group. 
Table 2: Primary and secondary maternal outcomes
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appropriate. All binary outcomes were analysed with a 
binomial regression model with a log link. Test 
performance was evaluated with sensitivity, specificity, 
positive and negative predictive values, and positive and 
negative likelihood ratios. Mixed-effects log-normal 
regression curves were generated for the proportion of 
women diagnosed relative to time from trial entry. 
Health-care resource use was analysed with generalised 
linear mixed models with linear time-fixed effects and 
random effects for centre. We chose the best performing 
model (using suitable family and link functions) based 
on the lowest Akaike Information Criteria.
To account for the stepped-wedge design and potential 
for selection bias, differences in prespecified, clinically 
relevant baseline characteristics were tested with logistic 
regression for binary variables and ordered logistic 
regression for ordered categorical variables. If there were 
more than 5% of participants with missing data for 
the primary outcome, further adjustment would be 
considered. All outcomes were adjusted for centre and 
categorical time effects because of the trial design. Effects 
were estimated with multiple regression, including 
terms for the intervention with fixed effects using 
dummy variables at each time in each centre. Centre was 
considered as a categorical variable and fitted as separate 
dummy variables for each centre. Calendar time was 
treated as a single categorical time variable.
On central review, some women were identified as 
having fulfilled the ISSHP criteria for pre-eclampsia but 
were never given this diagnosis by the clinical team, 
and hence were missed. These women were recorded 
as having pre-eclampsia by adjudication but were not 
included in the prespecified primary outcome analysis 
because they did not have a clinical diagnosis of pre-
eclampsia. Results are reported as per CONSORT guide-
lines.21 All statistical analyses were done with Stata 
version 14.2 (StataCorp; College Station, TX). This trial is 
registered with ISRCTN, number 16842031.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between June 13, 2016, and Oct 27, 2017, 1035 women at 
11 maternity units were enrolled and assessed for their 
inclusion in the trial; 12 (1%) women were found to 
be ineligible (figure 1). Of the 1023 eligible women, 
576 (56%) women were included in the trial while their 
maternity unit was allocated to the intervention (revealed 
testing) group, and 447 (44%) women were included in 
the trial while their maternity unit was allocated to the 
concealed testing group. All women allocated to the 
revealed testing group received this intervention, but only 
436 (98%) women allocated to the concealed testing 
group received this treatment because samples from nine 
women at one site were not processed due to an 
administrative error, and a sample was not ob tained from 
two women at other sites. Three (1%) women in the 
revealed testing group were lost to follow-up, so 
573 (99%) women in this group were included in the 
analyses. One (<1%) woman in the concealed testing 
group withdrew consent to follow-up data collection, so 
446 (>99%) women in this group were included in the 
analyses. No further analyses were needed to account for 
missing data (in <1% of women).
There was no contamination between the trial groups—
ie, no National Health Service identification numbers 
were duplicated in the database. The trial team kept strict 
logs of supply and use of the Triage PlGF cartridges, and 
a consent form was required to use each kit. There were 
no unauthorised tests on the data downloads from the 
Triage meters. The number of women recruited by trial 
centre is shown in the appendix. Participant characteristics 
are shown in table 1. The two groups were comparable at 
trial entry, and no substantial differences were observed 
in baseline variables.
In the concealed testing group, low PlGF (<100 pg/mL) 
concentrations had a high accuracy in determining pre-
eclampsia that required delivery within 14 days; this test 
had high sensitivity (94·9%) and negative predictive 
values (98·3%) in women presenting before 35 weeks of 
gestation (appendix). In women presenting between 
35 weeks and 0 days and 36 weeks and 6 days of gestation, 
the sensitivity was 96·2% and the negative predictive 
value for delivery before 37 weeks was 97·1%.
The median time to diagnosis of pre-eclampsia was 
1·9 days in the revealed testing group versus 4·1 days in 
the concealed testing group. The time ratio was 0·36 
(95% CI 0·15–0·87; p=0·027), corresponding to a 
64% reduction in time to diagnosis (13–85%; table 2). The 
intra-cluster correlation for the primary outcome was 
0·035. 205 (36%) women in the revealed testing group 
and 155 (35%) women in the concealed testing group were 
diagnosed with pre-eclampsia. The mixed-effects log-
normal regression curves of the proportion of women 
diagnosed by time from trial entry with revealed versus 
concealed PlGF testing are shown in figure 2. More 
women were diagnosed within 24 h of enrolment in the 
revealed testing group (52 [20%] women) compared with 
those in the concealed testing group (31 [16%] women; 
adjusted odds ratio [aOR] 3·6, 95% CI 1·16–11·20; 
p=0·027). The incidence of severe pre-eclampsia did not 
differ between the groups (1·22 [0·71–2·12])
Severe maternal adverse outcomes22 were less frequent 
in the revealed testing group than the concealed testing 
group (22 [4%] vs 24 [5%] events; aOR 0·32, 95% CI 
0·11 to 0·96; p=0·043). There were five serious events 
(two eclamptic fits, two strokes, and one cardiac arrest in 
four women, all of whom had low PlGF concentrations) 
in the concealed testing group, whereas there were no 
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similarly serious events in the revealed testing group 
(table 2). A higher proportion of women in the concealed 
testing group than the revealed testing group received 
transfusion of blood products (14 [3%] vs 9 [2%]). The 
highest mean systolic blood pressure, use of antihyper-
tensive medic ation, and use of magnesium sulphate did 
not differ between groups. More women in the revealed 
testing group than the concealed testing group received a 
fetal ultrasound (438 [77%] vs 307 [69%] women) and a 
higher umbilical artery pulsatility index was seen in the 
revealed testing group (more than the 95th percentile in 
66 [16%] vs 27 [9%] women; 2·94, 1·07 to 8·11). The number 
of fetuses with a birthweight of less than the tenth centile 
(1·49, 0·70 to 3·15) and those with absent or reversed 
end diastolic flow rates (1·82, 0·56 to 5·90) did not 
differ between the groups. Both groups showed a similar 
frequency of pre-labour caesarean sections. Delivery 
gestation did not differ significantly between the groups 
(36·6 weeks in the revealed testing group vs 36·8 weeks in 
the concealed testing group; mean difference –0·52, 
95% CI –0·63 to 0·73).
The composite adverse perinatal outcome did not differ 
between the groups: 85 (15%) fetuses in the revealed 
testing group and 63 (14%) fetuses in the concealed testing 
group had adverse events (aOR 1·45, 95% CI 0·73–2·90; 
table 3). We observed no differences in the prevalence of 
spontaneous vaginal delivery (1·05, 0·59–1·86), or the use 
of pre-labour caesarean sections (0·96, 0·59–1·55) or in-
labour caesarean sections (0·78, 0·48–1·25) between the 
groups. We also observed no differences in perinatal 
deaths, preterm delivery before 37 weeks of gestation 
(1·00, 0·61–1·63), birth weight centiles, neonatal unit 
admissions, gestation at delivery, or indication for delivery 
with PlGF testing (appendix).
Prespecified serious adverse events are shown in 
table 4. No maternal serious adverse events were reported 
in the revealed testing group versus five events in 
four (1%) women in the concealed testing group. There 
were similar numbers of fetal and neonatal deaths in 
both groups (ten deaths in the revealed testing group 
versus seven deaths in the concealed testing group). We 
found that a low circulating PlGF concentration preceded 
all morphologically normal fetuses that were stillborn 
except one (table 4).
A similar proportion of women met the diagnostic 
criteria for pre-eclampsia after adjudication in both 
groups (255 [44%] women in the revealed testing group 
and 197 [44%] women in the concealed testing group). In 
women diagnosed with pre-eclampsia by adjudication, 
diagnosis was reached by the treating clinicians in 
205 (80%) women in the revealed testing group compared 
with 155 (79%) women in the concealed testing group.
The revealed testing group had a mean of 6·14 (SE 0·53) 
antenatal outpatient attendances versus 9·44 (0·81) 
visits in the concealed testing group; however, this dif-
ference was removed after negative binomial regression 
adjustment for calendar time (negative binomial –0·04, 
95% CI –0·23 to 0·16). Women in the revealed testing 
group spent a mean of 7·43 (SE 0·36) nights in inpatient 
care, versus 7·26 (0·38) nights in the concealed testing 
group (–0·06, –0·22 to 0·09). Women in the revealed 
testing group used the highest levels of neonatal care 
(intensive and high-dependency care nights) to a lesser 
extent (a mean of 15·2 [SE 1·7] nights vs 24·2 [3·8] nights 
Figure 2: Proportion of women diagnosed with pre-eclampsia when revealing versus concealing circulating 
placental growth factor concentrations from clinicians, over days (A) and weeks (B) 
Data are mixed-effects log-normal regression curves.
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Time from trial entry to diagnosis (days) Time from trial entry to diagnosis (weeks)
Revealed (intervention)
Concealed 
Revealed PlGF 
(intervention; n=573)
Concealed PlGF 
(n=446)
Gestation at delivery, weeks 36·6 (3·0) 36·8 (3·0)
Vital status at birth
Livebirth 567 (99%) 440 (99%)
Intrauterine fetal death 7 (1%) 6 (1%)
Perinatal adverse outcomes* 86 (15%) 63 (14%)
Composite perinatal adverse outcome components
Any grade of intraventricular haemorrhage 7 (1%) 11 (3%)
Seizure 0 2 (<1%)
Any grade of retinopathy of prematurity 9 (2%) 9 (2%)
Respiratory distress syndrome 78 (14%) 54 (12%)
Bronchopulmonary dysplasia 5 (1%) 3 (1%)
Necrotising enterocolitis (stage 2 or 3) 7 (1%) 7 (2%)
Perinatal deaths 6 (1%) 4 (1%)
Late neonatal deaths (8–27 complete days of life) 3 (1%) 1 (<1%)
Neonatal unit admission 195 (34%) 146 (33%)
Birthweight, g 2657 (887) 2720 (858)
Birthweight centile 42·8 (33·0) 43·4 (33·1)
Apgar score at 5 min after delivery 9·14 (1·52) 9·24 (1·41)
Umbilical arterial pH at birth 7·25 (0·11) 7·23 (0·09)
Umbilical arterial pH <7·2 at birth 141 (25%) 135 (30%)
Perinatal health resource use (in those admitted)
Inpatient nights in the neonatal unit 22·1 (25·9) 24·6 (35·2)
Nights in the intensive care or high-dependency units 15·2 (1·7) 24·2 (3·8)
Nights in the special care baby unit 14·7 (14·4) 13·09 (12·6)
Data are mean (SD), n (%), or median (IQR). Fetuses could have one or several composite perinatal adverse 
components. PlGF=placental growth factor. *Only components with an outcome are included here; full details are 
shown in the appendix.
Table 3: Secondary perinatal outcomes
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in the concealed testing group (mean difference –10·6, 
95% CI –20·81 to –0·47), and we found no difference 
between the groups in the number of nights spent in the 
special care baby unit.
Discussion
Our trial has shown that, in women presenting with 
suspected pre-eclampsia, PlGF measurement, incor-
porated into a management algorithm based on national 
guidelines, significantly reduces the time taken for 
treating clinicians to diagnose pre-eclampsia. This 
improvement was associated with a significant reduction 
in maternal adverse outcomes, with no detected dif -
ference in gestational age at delivery or adverse perinatal 
outcomes. Revealing PlGF results did not change the 
clinical indications for elective early delivery within our 
trial population. Additionally, we found no increase in 
neonatal unit admissions, but we noted a reduction in the 
use of higher levels of neonatal care when revealing PlGF 
results. For more than 100 years, pre-eclampsia diagnosis 
has relied on poorly reproducible clinical signs, such as 
blood pressure and proteinuria; PlGF measure ment could 
present a change for antenatal care that improves not only 
diagnosis, but also management and pregnancy outcome.
To our knowledge, this is the first multicentre ran-
domised controlled trial of PlGF measurement as a 
diagnostic adjunct for pre-eclampsia. Trials to assess the 
effects of such tests on clinical care are uncommon. The 
Patient Centred Outcomes Research Institute recom-
mend that process of care outcomes (such as time to 
procurement of a definitive diagnosis) should be used 
to evaluate diagnostic tests alongside patient-centred 
outcomes such as morbidity or mortality outcomes.23 This 
recommen dation reflects the need for trials of diagnostic 
tests to evaluate both the benefits of the intervention in a 
diagnostic capacity, and also the effects on downstream 
clinical outcomes. A reduction of around 2 days in 
clinicians reaching a diagnosis of preterm pre-eclampsia 
is important for decision making in a disease with a 
substantial degree of diagnostic uncertainty. Such a 
decision would usually affect the care pathway regarding 
the place and frequency of management (including 
whether to transfer the pregnant woman to a hospital 
with an appropriate neonatal care facility), avoidance of 
severe morbidity, administration of steroids for fetal lung 
maturity, and timing of delivery. The ability to diagnose 
pre-eclampsia more rapidly enables targeted, individ-
ualised management. There is a double benefit of 
appropriately reassuring women who do not need 
intensive investigation and minimising excessive health 
service use for those at lower risk within this acute period 
of diagnostic ambiguity.
We managed women in both trial groups in accordance 
with the national guidelines on the management of 
hypertension in pregnancy. However, the revealed PlGF 
group received the results of their PlGF measurement 
incorporated into this clinical guidance. This was a 
pragmatic trial, to reflect how angiogenic factor 
measurement could be adopted clinically and real istically 
within a health-care service. We provided simple guidance 
around the blood test result (as would be given in usual 
practice), with clinical management decisions of indi-
vidual pregnant women left to the discretion of the 
treating clinician, including future assessments and 
schedules of care. The trial intervention was, of necessity, 
not masked to clinicians, and we hypothesised that the 
intervention might affect diagnostic decisions and 
management. We have aimed to report not only the test 
accuracy of PlGF, but its effect on the process and health 
outcomes of the pregnant women,23 mediated through 
clinician behaviour.
The trial was intentionally designed to evaluate real-
world effectiveness of the intervention24 rather than 
efficacy in ideal conditions by mimicking adoption of the 
diagnostic test into clinical practice across several sites. 
Our trial included an assessment of process, clinical 
outcomes, and health resource use to evaluate the effects 
of the intervention across these domains.
The strengths of our study include that it comprised a 
robust evaluation of a test on both real-world diagnostic 
performance and clinical effects (beyond demonstrating 
test accuracy), the generalisability of the findings through 
testing across several sites, and inclusion of an ethnically 
and sociodemographically diverse population. The broad 
inclusion criteria for testing relate to usual antenatal 
presentations to obstetric triage. The provision of the 
management algorithm and short training package, with 
individual patient management left to the discretion of 
the treating clinician, reflect how PlGF testing might be 
used if adopted more widely. We anticipate that these 
findings would be generalisable to similar settings in 
Revealed PlGF 
(intervention; 
n=573)
Concealed PlGF 
(n=446)
Number of women with maternal 
adverse events
0 4 (1%)
Maternal death 0 0
Maternal stroke 0 2 (<1%)
Maternal cardiac arrest 0 1 (<1%)*
Eclampsia 0 2 (<1%)
Number of babies with perinatal 
serious adverse events
10 (2%) 7 (2%)
Intrauterine fetal death
Before viability† 3 (1%); 2 3 (1%); 3
Viable (no fetal dysmorphism) 1 (<1%); 1 3 (1%); 2‡
Viable (fetal dysmorphism noted) 3 (1%); 1 0
Neonatal deaths 3 (1%); 3 1 (<1%); 1
Data are n (%); for fetal events, the number of mothers with a PlGF concentration 
of less than the fifth centile is presented after the semicolon. PlGF=placental growth 
factor. *This cardiac arrest occurred as an additional event to a stroke. †Less than 
24 weeks of gestation or less than 500 g. ‡One sample was not processed.
Table 4: Prespecified serious adverse events
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which pregnant women present to physicians with 
suspected pre-eclampsia for assessment. All diagnoses 
were reviewed by the trial team, who were masked to trial 
allocation, with stringent diagnostic criteria. The analysis 
followed a prespecified analysis plan. Our trial also had 
some limitations: it was restricted to women with 
singleton pregnancies before 37 weeks of gestation and 
the findings might not be generalisable to pregnancies 
with multiple fetuses and those presenting with late-
onset pre-eclampsia after 37 weeks of gestation, although 
women with gestational hypertension or confirmed pre-
eclampsia presenting after 37 weeks of gestation are 
usually managed with planned delivery rather than 
surveillance.25 Because the greatest challenges associated 
with diagnostic uncertainty relate to women presenting 
before 37 weeks of gestation, in whom maternal and 
perinatal morbidity associated with pre-eclampsia is 
greatest, our trial has addressed an important time 
period in clinical management of pre-eclampsia. We 
chose a stepped-wedge design because we were aiming 
to introduce a biochemical test and associated manage-
ment algorithm, necessitating change in practice across 
a service. Women and investigators were clear that this 
was their preferred study design because individual 
randomisation was perceived to be unfeasible, inequi-
table, and prone to contamination. However, this 
trial type might have confounding effects because of 
secular trends in calendar time, related to sequential 
implementation of the intervention across participating 
units, a potential limitation of such a design. We found 
a difference in recruitment numbers between the 
revealed and concealed testing groups due to higher 
recruitment numbers in later blocks (when more sites 
had transitioned to revealed testing). However, we did 
not restrict recruitment in the later stages of the trial to 
avoid selection bias. It is possible that the increase in 
numbers recruited in the intervention group could be a 
form of selection bias in itself, with clinicians recruiting 
different women due to the test becoming available, or 
that revealing the test result could affect the diagnosis of 
pre-eclampsia itself; these biases do not appear to be 
substantial because the baseline characteristics and the 
proportion diagnosed with pre-eclampsia were similar 
across both groups. Future stepped-wedge trials could 
consider a run-in phase, to mitigate against lower 
recruitment in the early months relative to later months.
Previous studies11,20,26,27 have used a cohort design to 
investigate the potential usefulness of angiogenic factors 
for diagnosis of pre-eclampsia in women presenting with 
suspected pre-eclampsia, rather than randomised trials. 
We found similar test performance statistics in our 
concealed testing group to those seen in other large 
cohort studies11,20 and clinical evaluation studies.26,27 We 
did not report test performance in the intervention group 
to avoid the test performance for diagnosis of pre-
eclampsia being affected by knowledge of the test result. 
We reported an additional perinatal composite outcome 
similar to that used previously26 to enable evaluation of 
the effects of the intervention on perinatal outcomes. We 
used PlGF testing, rather than the soluble fms-like 
tyrosine kinase 1/PlGF ratio as used in other studies.20 
Evidence has shown that the commercially available tests 
compare similarly in their prediction of need for delivery 
within 14 days;28 we anticipate that these results would 
be generalisable in similar settings that use alternative 
PlGF assays. Other studies have assessed the detection 
frequency of subsequent pre-eclampsia by use of a 
combination of maternal factors, including mean arterial 
pressure, uterine artery pulsatility index, serum PlGF, 
and serum soluble fms-like tyrosine kinase-1 in un-
selected populations of women at fixed timepoints 
(eg, 20 weeks and 36 weeks).29,30 External validation and 
economic analysis of these algorithms are awaited.
Suspected pre-eclampsia is one of the most frequent 
presentations to antenatal services, and current methods 
to risk stratify women are inadequate for accurate 
prediction of adverse outcomes. Our trial was powered 
to show a reduction in the time to diagnosis of pre-
eclampsia and has shown that clinical use of PlGF does 
facilitate earlier diagnosis. More timely management, 
particularly relating to targeted surveillance of women 
at increased risk, could contribute to a reduction 
in maternal adverse events. The composite of severe 
maternal adverse outcomes was a prespecified secondary 
outcome measure, but the reduction found in the 
revealed testing group could be a chance finding 
requiring circumspect interpretation.
Low PlGF concentrations have been shown to have 
high sensitivity and negative predictive values for 
intrauterine fetal death,11 as confirmed in our trial. For 
pregnancies complicated by fetal growth restriction with 
a viable fetus between 26 and 32 weeks of gestation, there 
is evidence from long-term neurodevelopmental follow-
up that management should be directed by monitoring 
of the ductus venosus waveform and computerised 
cardiotocography.31 Earlier confirmation of placental 
dysfunction in suspected fetal growth restriction by use 
of PlGF has the potential to improve risk stratification 
and target surveillance. However, given the low numbers 
of stillbirths in our study, further work is required to 
investigate the usefulness of PlGF for the prevention of 
later stillbirths.
In the revealed testing group, we found a lower duration 
of intensive and high-dependency care received by infants 
relative to the concealed testing group. Maternal health-
care resource use did not differ be tween the groups. 
These findings might reflect more appropriate antenatal 
surveillance in at-risk pregnancies, including earlier 
recognition of fetal compromise and more timely delivery, 
with more appropriate stratification of those at lower risk.
Previous cohort studies11,20 have suggested that test 
performance of angiogenic markers is accurate in ruling 
out pre-eclampsia. Further work is needed to clarify 
the potential effects on maternal and perinatal adverse 
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outcomes as a primary powered endpoint, and studies are 
ongoing. Angiogenic markers vary throughout gestation, 
and there is a paucity of evidence regarding acute changes 
in angiogenic markers in pregnancies with persistent 
clinical disease suspicion. Our trial did not assess repeat 
PlGF testing in women with recurrent presentations 
who remained undiagnosed, and the optimum timing 
of repeat sampling remains uncertain. Furthermore, 
although our trial has evaluated the usefulness of PlGF 
with categories based on centile thresholds11 there could 
be additional benefit to the use of PlGF as a continuous 
measurement, in a similar manner to other clinically 
used biochemical variables. Finally, PlGF measurement 
could also be used in prognostic stratification after pre-
eclampsia is con firmed as a diagnosis, particularly at 
gestations in which the balance between risks to mother 
and baby are difficult to judge.
In conclusion, the findings of our trial provide novel 
evidence supporting the adoption of PlGF testing as a 
diagnostic adjunct in women presenting with suspected 
pre-eclampsia.
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